Current Therapies are Symptomatic

Autism spectrum disorder (ASD) is a developmental disorder, characterized by deficits in communication, social interactions and sensory perception and by repetitive behavior, typically manifesting in the first three years of life. No curative therapies are available to treat the condition, since its causes remain poorly understood.

Thus, current therapeutic approaches to ASD are symptomatic. However, symptomatic treatments fail to address core etiological factors. Therapeutic options must be tailored to address the specific diagnostic findings of each individual. Early intervention is often associated with substantial improvements.

Unfortunately, despite intensive behavioral, psychological and/or educational therapies and pharmaceutical treatment to minimize symptoms, many individuals fail to show significant improvement. Even some response to treatment will enable subjects to benefit from psychological/behavioral therapy, which would give them more independence and reduce lifelong support and family stress.

Innovative Stem Cell Therapies are Causative-Curative

Contemporary researchers and the medical community are exploring the potential use of stem cells (SCs) for many medical conditions due to their unique therapeutic properties, both in tissue regeneration and immune modulation. Given their high safety profile, SCs qualify to be a promising option for the treatment of ASD in terms of potential to restore normal immunological function.


SCs are easily isolatable and self-renewing cells with the ability to differentiate into a broad range of specialized cell types. SCs have been appreciated for their benefits in treating disease, particularly by driving tissue repair and immuno-modulatory responses. SC transplants (from another individual) and re-implants (autologous, from the patient’s own system) are routinely performed as standard treatment for oncological diseases following intense radiotherapy or chemotherapy. In recent years, autologous SCT has been assessed for its impact on a number of degenerative and inflammatory diseases and shown to improve symptoms.

Stem Cell Therapy for ASD

Epidemiological and immunological evidence points to an immune etiology in a subset of children with ASD. Cell-El’s preliminary data from its diagnostic study confirm this observation. Thus, SC infusion may have a curative impact on ASD, and data from our experience and the literature support this concept. Optimal dosage, ideal age for treatment, and number and timing of treatments remain open questions for our clinical research. Cell-El seeks to more comprehensively assess the effect of autologous SCT on young ASD patients. Our clinical work focuses on younger patients, since at this stage brain plasticity remains high and more responsive to immuno-modulation.

Autologous SCT – Description of the Procedure

SCs are collected from the sedated patient with mild and short-acting anesthesia. 3-5 mL/kg body weight of bone marrow are removed from the hipbone, which typically does not cause any side effects. The aspirated bone marrow is processed on-site, then re-injected back into the patient within 30-60 minutes.

bone marow

Bone Marrow aspiration

Lumbar Puncture

Treatment with Bone Marrow-Derived Stem Cells (BM-SC)

1. Evaluation

  • Clinical (ADOS…)
  • Laboratory (serum, stool urine)

<1 month pre-treatment


2. Bone Marrow Aspiration (3-5 ml/kg body weight) → separated in Operating Room

3. Administration

4. Evaluation
  • Clinical (ADOS…)
  • Laboratory (serum, stool urine)
1 + 3 + 6 months post-treatment

Steps 2 and 3 are under mild sedation, < 1 hour, ambulatory

Monitoring after SCT

ASD status will be monitored at 1, 3, 6 months after the SCT for psychological and laboratory evaluations

Further reading: Therapeutic properties of mesenchymal stem cells for autism spectrum disorders, Medical Hypotheses

If you are interested in finding out more about our diagnostic and therapeutic studies, please contact us.


Cell-El’s research has identified an association between the immune system and ASD. Based on these findings, Cell-El seeks to treat young children with their own (autologous) SCs. For more information, please read our Diagnostics and Therapy (this) pages.

The mechanism by which SCs provide targeted treatment for ASD is modulating the underlying immune dysfunction as well as improving the function and regeneration of normal brain tissue. In young children, brain plasticity, or the capacity to regenerate brain tissue, is particularly high. The synergistic effect of immune modulation and brain tissue regeneration may lead to a significant clinical improvement.

Therapeutic Rationale of MSC for ASD

  • Chronic autoimmune reaction
  • Neurogenesis ↓ (neuro-developmental disorder)

Therapeutic Rational of MSC for ASD

Due to the dual properties of MSC, suppressing immune dysfunction while promoting neurogenesis, 

MSC may be appropriate therapy for ASD,  in particular in young children (“brain plasticity”). Synergistic Effect (1+1>2)

To date, autologous stem cell therapy (SCT) has proven safe and effective. Short-term side effects may include headache and dizziness that resolves quickly.

Further reading: Research has shown that Stem Cells are Safe and Feasible in Young Children with ASD. Read more

Cell-El’s team has been researching the connection between ASD, immune dysfunction and SCs for more than five years. We have published our studies and submitted protocols to international regulatory authorities. We are already seeing indications of positive clinical success. Our study has approvals from the Helsinki Ethics Committees and the Israeli Ministry of Health. We are expanding our study through the European Medicines Agency (EMA) and with several academic centers abroad.


Cell-El plans to launch a therapeutic study.  Please fill in the form below to receive updates.

Yes! I would like to subscribe to the Cell-El mailing list

Cell-El pioneers a therapeutic study using the patient’s stem cells based on clear biological immune dysfunction in children with ASD.

Cell-El is the first study to suggest stem cell treatment based on clear biological immune dysfunction in children with ASD. As the study expands from diagnostic to therapeutic, Cell-El looks forward to showing the correlation between the modulated immune system of the child with ASD after stem cell therapy (SCT) and their improved behavior. Thereby demonstrating that the behaviors of ASD are rooted in a biological basis that can be treated. Cell-El is proud to be the first to offer innovative autologous* mesenchymal stem cell (MSC) therapy as part of a comprehensive study both prior to and after treatment.

*One’s own stem cells

Cell-El’s planned therapeutic approach is to treat young children with their own (autologous) stem cells. 

To date stem cell therapy from the patient’s own body (“autologous”) has shown to be safe and effective. Short-term side effects sometimes include a headache and dizziness that resolves quickly.